Many methods for reducing the immunosuppressive requirements of allotransplantation
have been proposed based on a growing understanding of physiological and allospecific …

The prevention of allograft transplant rejection by inhibition of the CD40/CD40L
costimulatory pathway has been described in several species. We searched pubmed for …

Prior studies of anti-CD40 ligand (CD40L)–based immunosuppression demonstrated
effective prevention of islet and kidney allograft rejection in nonhuman primate models; …

CD154 is a cell surface molecule expressed on activated T cells that binds to CD40, an
activating molecule on APCs. Its blockade has been shown to prevent allograft rejection …

Background. Anti-CD154 monoclonal antibodies (mAbs) cause long-term graft survival in
preclinical allotransplantation experiments. This is the first report on the efficacy and safety …

Background. This study assesses the safety and efficacy of the novel human anti-human
CD154 monoclonal antibody ABI793 in rhesus monkeys. Methods. Outbred rhesus monkeys …

Given the significant morbidity associated with current post-transplant immunosuppressive
regimens, induction of immune tolerance continues to be an important goal of clinical organ …

Anti-CD154 variably prolongs allograft survival in nonhuman primates. Rodent studies
suggest that adding pretransplant donor-specific transfusion (DST) and/or rapamycin to anti …

Background. Antibodies and fusion proteins specific for CD80, CD86, and CD154 have
shown promise as agents capable of inducing donor-specific tolerance in rodents. These …

Large animal models have long served as the proving grounds for advances in
transplantation, bridging the gap between inbred mouse experimentation and human …